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Having collaborated with Anthony Morrison for a number of years, there is no doubt in my 
mind that his primary objective is to improve the acceptability, effectiveness and safety of 
interventions for people with psychosis. In his article (A. P. Morrison, 2018) he is correct to 
say the effectiveness of antipsychotics have been overestimated and the adverse effects 
underestimated (Hutton et al., 2012; Hutton, Taylor, Mulligan, Tully, & Moncrieff, 2015; 
Leucht et al., 2017; Anthony P. Morrison, Hutton, Shiers, & Turkington, 2012), and he 
should be commended for producing world-leading evidence on the effectiveness and safety 
of alternative approaches, such as cognitive behavioural therapy (CBT) (Anthony P Morrison 
et al., 2014). We also agree that people with psychosis need much more choice regarding the 
interventions offered to them (Diana Stovell, Wearden, Morrison, & Hutton, 2016), That 
being said, a number of arguments he raised in his commentary do not withstand scrutiny.  
 
First, he downplays the possibility that psychological interventions such as CBT cause harm. 
As he and I have discussed on several occasions, the measurment and reporting of adverse 
effects in trials of psychological interventions for psychosis (and other conditions) is 
extremely poor. Although he agrees we need to change this, as acknowledged in his article 
and as reflected in the adverse effect monitoring protocol that we developed for his recent 
trial (Pyle et al., 2016), one obstacle to doing so is complacency on the part of leaders in the 
field. Trials are rarely powered to detect adverse effects, meaning the absence of significant 
effects in the selected trials that have measured this does not prove evidence of absence. 
Thus, it is imperative that we do not jump to conclusions or offer false reassurance. 
 
Second, and perhaps more importantly, his statement that many inpatients with psychosis 
have capacity to make decisions about their treatment both minimises and sidesteps a number 
of serious issues. We know that between 50% and 80% of inpatients with psychosis are 
judged to lack treatment decision-making capacity (Okai et al., 2007) and we know that this 
is likely to lead to involuntary and coercive treatment (Larkin & Hutton, 2017). Denying this 
clinical reality will simply result in an impasse between those who work with acutely unwell 
patients with psychosis and those who wish to develop more benign treatments, but the only 
people who will suffer from this are people with psychosis. Although he notes our meta-
analysis of shared treatment decision-making found this approach can improve subjective 
empowerment (D. Stovell, Morrison, Panayiotou, & Hutton, 2016), he does not mention our 
finding that it does not seem to lead to improved capacity. 
 
We have argued elsewhere that researchers and clinicians should invest significant time and 
effort into developing effective ways to help people with psychosis regain and retain 
treatment decision-making capacity (Larkin & Hutton, 2017). Ideally, this would involve 
working collaboratively with people with psychosis and their clinicians to identify and reduce 
internal threats to capacity, such as symptoms and cognitive impairmemt, but also external 
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threats, such as coercion and provision of partial information (Burns et al., 2011; Larkin & 
Hutton, 2017). Failure to develop this evidence will simply lead to people with psychosis not 
receiving effective decision-making support. 
 
If we wish to truly improve outcomes for people with psychosis, we need to dedicate 
ourselves to researching the benefits and costs of our interventions and we need to do all we 
can to support them to make their own decisions. This requires full committment by leaders 
in the field, and nothing less. 
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